- Home
- QTTB vs GPAT Comparison
QTTB vs GPAT Comparison
Compare QTTB & GPAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- GPAT
- Stock Information
- Founded
- QTTB 2015
- GPAT 2020
- Country
- QTTB United States
- GPAT United States
- Employees
- QTTB N/A
- GPAT N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- GPAT
- Sector
- QTTB Health Care
- GPAT
- Exchange
- QTTB Nasdaq
- GPAT NYSE
- Market Cap
- QTTB 434.0M
- GPAT 364.4M
- IPO Year
- QTTB N/A
- GPAT 2024
- Fundamental
- Price
- QTTB $3.31
- GPAT $10.15
- Analyst Decision
- QTTB Buy
- GPAT
- Analyst Count
- QTTB 8
- GPAT 0
- Target Price
- QTTB $29.14
- GPAT N/A
- AVG Volume (30 Days)
- QTTB 690.6K
- GPAT 67.2K
- Earning Date
- QTTB 11-07-2024
- GPAT 01-01-0001
- Dividend Yield
- QTTB N/A
- GPAT N/A
- EPS Growth
- QTTB N/A
- GPAT N/A
- EPS
- QTTB N/A
- GPAT 0.30
- Revenue
- QTTB N/A
- GPAT N/A
- Revenue This Year
- QTTB N/A
- GPAT N/A
- Revenue Next Year
- QTTB N/A
- GPAT N/A
- P/E Ratio
- QTTB N/A
- GPAT $33.60
- Revenue Growth
- QTTB N/A
- GPAT N/A
- 52 Week Low
- QTTB $3.02
- GPAT $9.98
- 52 Week High
- QTTB $53.79
- GPAT $10.16
- Technical
- Relative Strength Index (RSI)
- QTTB 16.87
- GPAT N/A
- Support Level
- QTTB $3.02
- GPAT N/A
- Resistance Level
- QTTB $3.77
- GPAT N/A
- Average True Range (ATR)
- QTTB 1.69
- GPAT 0.00
- MACD
- QTTB -0.34
- GPAT 0.00
- Stochastic Oscillator
- QTTB 1.16
- GPAT 0.00
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.